Objective. Diabetes is characterized by pancreatic β-cell dedifferentiation. Dedifferentiating βcells inappropriately metabolize lipids over carbohydrates and exhibit impaired mitochondrial oxidative phosphorylation. However, the mechanism linking the β-cell's response to an adverse metabolic environment with impaired mitochondrial function remains unclear.Methods. Here we report that the oxidoreductase cytochrome b5 reductase 3 (Cyb5r3) links FoxO1 signaling to β-cell stimulus/secretion coupling by regulating mitochondrial function, reactive oxygen species generation, and NAD/NADH ratios.Results. Expression of Cyb5r3 is decreased in FoxO1-deficient β-cells. Mice with β-cell-specific deletion of Cyb5r3 have impaired insulin secretion resulting in glucose intolerance and dietinduced hyperglycemia. Cyb5r3-deficient β-cells have a blunted respiratory response to glucose and display extensive mitochondrial and secretory granule abnormalities, consistent with altered differentiation. Moreover, FoxO1 is unable to maintain expression of key differentiation markers in Cyb5r3-deficient β-cells, suggesting that Cyb5r3 is required for FoxO1-dependent lineage stability.Conclusions. The findings highlight a pathway linking FoxO1 to mitochondrial dysfunction that can mediate β-cell failure. Fan et al., Cyb5r3 and β-cell failure Glp1 agonists show increased durability compared to other treatments [4], they are insufficient to halt disease progression [5; 6].There are several pathways to β-cell failure [2]. Our work focuses on β-cell dedifferentiation as a mechanism of β-cell dysfunction [7][8][9][10][11][12][13]. We and others have described a signaling mechanism by which excessive or altered nutrient flux, in combination with an adverse hormonal or inflammatory milieu, results in a stress response orchestrated by (but not limited to) the transcription factor FoxO1 [14; 15]. The failure of this homeostatic mechanism affects mitochondrial function [16]. We have proposed that dedifferentiation is the end result of altered mitochondrial substrate utilization, or "metabolic inflexibility" [17]. The implication of this model is that therapeutic reversal of mitochondrial dysfunction may prevent dedifferentiation or even promote "redifferentiation" of β-cells. However, the effectors of mitochondrial dysfunction in this model remain unclear. In previous work, we used a combination of marker analysis and RNA profiling to compile a list of potential effector genes of β-cell failure [18]. Although several interesting candidates emerged from that work, functional evidence for their role in diabetes progression is lacking.Among candidates identified in the RNA profiling of dedifferentiating β-cells is Cyb5r3.This gene encodes a flavoprotein with membrane-bound and soluble forms, the latter of which is restricted to erythrocytes [19]. Mutations of this form lead to recessive congenital (Type I) Fan et al., Cyb5r3 and β-cell failure 4 methemoglobinemia, while mutations in the membrane-bound form can cause severe neurological disease (Type II)...